We Believe Pharmacyclics Shares Are Positioned For Growth, Says Roth Capital
Pharmacyclics (PCYC) yesterday announced 2Q14 results, posting EPS of ($0.49) and revenue of $113.0 million. In the last week, Imbruvica received full approval in the U.S. and a positive opinion from the European CHMP, signaling that E.U approval could come in 2-3 months.
As a result, Roth Capital analyst Joseph Pantginis today reiterated a Buy rating on PCYC with a $183 price target, as he believes that PCYC and partner Janssen (JNJ) will deliver a strong success story with Imbruvica, both in current indications and as the profile of the drug possibly expands, going forward. The analyst also believes that PCYC shares are positioned for growth.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a -9.5% average return and a 33.0% success rate. Pantginis has a 7.5% average return when recommending PCYC, and is ranked #3156 out of 3195 analysts.